SCYNEXIS Inc SCYX

Healthcare

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

NDAQ:SCYX - Post by User

SCYNEXIS Inc

Bullboard Posts

Post by dmacdon Feb 11, 2019 10:00pm

88 Views

Post# 29350598

Price Target

Updated presentation
https://d1io3yog0oux5.cloudfront.net/_72b6863745931dca7744e067d6bcf3be/scynexis/db/334/2840/pdf/SCYX_Corporate_Presentation_Feb+2019.pdf

Possible for the SP to go upwards of 15x if the testing over the next year is successful. Potential sales of $200 to over $500M/yr suggests a $0.5 to 3 billion valuation so lets go with a billion.

Merck will try to grab this for themselves and maybe there will be a bidder war since Ibrexa could put a few companies out of business. Anything less than 5x and I would prefer to see management ride out the wave.

This analyst has a $7.50/sh target (2 to 3 year) so like minded:
https://seekingalpha.com/article/4239770-scynexis-novel-antifungal-drug-life-threatening-resistant-infections-ridiculously-cheap

Fingers crossed ... we all need the good fortune to follow through to completion. Icing on the cake will be if they develop the IV formulation.

Bullboard Posts

Africa Oil collects more shares under buyback program